• Polymer Pen Lithography for 3D SERS Nanoclusters

  2026-08-18

  The reference study presents polymer pen lithography (PPL) as a route to highly ordered three-dimensional gold nanoparticle cluster arrays for surface-enhanced Raman scattering. By combining programmable polyethylenimine patterning with electrostatic nanoparticle assembly, the authors report an enhancement factor of 1.67 × 10^7 and a relative standard deviation below 4.73%, while retaining structural tunability.

• Carbapenemase Gene Transmission in CREC

  2026-08-18

  Chen et al. integrated resistance-gene localization, antimicrobial susceptibility testing, plasmid conjugation, mobile-element profiling, and ERIC-PCR genotyping to examine carbapenem-resistant Enterobacter cloacae across eight teaching hospitals in Guangdong. The findings identify blaNDM−1 as the dominant carbapenemase determinant and show substantial potential for both plasmid-mediated horizontal transfer and clonal dissemination.

• Nanoparticle mRNA Delivery to Reverse Trastuzumab Resistance

  2026-08-17

  Dong et al. developed a tumor-microenvironment-responsive nanoparticle platform for systemic PTEN mRNA delivery in trastuzumab-resistant HER2-positive breast cancer. The approach restored PTEN expression, inhibited PI3K/Akt signaling, and improved the antitumor activity of trastuzumab, while highlighting the formulation and biological barriers that govern therapeutic mRNA delivery.

• Annexin V-FITC/PI Apoptosis Assay Kit Workflow

  2026-08-17

  Use dual Annexin V-FITC and PI staining to separate viable, early apoptotic, and membrane-compromised cells in a rapid workflow. The assay is especially valuable when treatment studies need a phenotypic apoptosis endpoint linked to ROS, mitochondrial, or metabolic measurements.

• Palbociclib Beyond Monocultures: A Translational Playbook

  2026-08-16

  Palbociclib (PD0332991) is more than a selective CDK4/6 inhibitor: it is a mechanistic probe for testing how tumor–stroma interactions reshape cell-cycle dependence, drug response, and resistance. This thought-leadership guide connects the compound’s CDK4/6–Rb–E2F biology with patient-derived gastric cancer assembloids and offers a practical framework for translational breast cancer and renal cell carcinoma research.

• Staurosporine at the ECM–Kinase Interface

  2026-08-15

  A translational framework for using Staurosporine to interrogate how collagen architecture, kinase signaling, apoptosis, and angiogenesis interact in breast cancer models—without mistaking a broad perturbation tool for a single-target therapeutic proxy.

• Angiotensin 1/2 (1-6): From RAS to Translation

  2026-08-14

  Angiotensin 1/2 (1-6), the Asp-Arg-Val-Tyr-Ile-His hexapeptide, offers translational researchers a sequence-defined way to investigate renin-angiotensin system signaling, vascular tone, cardiovascular regulation, renal physiology, and an emerging connection to viral receptor biology.

• SD 169: Selective p38α/β MAPK Inhibitor

  2026-08-14

  SD 169, also called indole-5-carboxamide, is a selective ATP-competitive inhibitor of p38α and p38β MAPKs. Product information positions it for mechanistic studies of inflammatory signaling, type 1 diabetes research, apoptosis assays, and axonal regeneration research.

• Homoharringtonine Workflows for Cancer Biology

  2026-08-13

  Homoharringtonine is a cytotoxic alkaloid that connects protein-synthesis research, leukemia models, and carefully controlled antiviral assays. This guide translates its ribosome-directed activity into practical workflow design, assay controls, and troubleshooting strategies while separating research findings from clinical claims.

• Ratiometric Imaging of Amyloid-β Fibrils

  2026-08-13

  Wu and colleagues developed dual-emissive tris-heteroleptic ruthenium complexes that enable ratiometric fluorescence/phosphorescence detection of Aβ aggregation and confocal imaging of Aβ40 and Aβ42 fibrils. The study shows that complex 2 produces a stronger ratiometric response toward Aβ40 and illustrates how ligand tuning can improve both measurement reliability and imaging compatibility.

• Allosteric PDK4 Inhibitors: Evidence from Compound 8c

  2026-08-12

  This study identifies a new anthraquinone-derived series of allosteric pyruvate dehydrogenase kinase 4 inhibitors, with compound 8c emerging as the lead candidate. Its biochemical activity, metabolic stability, pharmacokinetic behavior, and efficacy in mouse models support further investigation while leaving important translational questions unresolved.

• GRE Inhibits Melanogenesis via CREB/MITF

  2026-08-12

  The reference study identifies glabridin, resveratrol, and ellagic acid (GRE) as a particularly effective in vitro combination for suppressing melanin production, tyrosinase activity, oxidative stress, and nitric oxide release. Its mechanistic contribution is the association of GRE activity with reduced CREB phosphorylation and downstream MITF signaling, while its cell-based design also defines important limits for translation to hyperpigmentation disorders.

• HRP Goat Anti-Mouse IgG (H+L) Antibody

  2026-08-11

  HRP Goat Anti-Mouse IgG (H+L) Antibody provides enzyme-based detection of mouse-derived primary antibodies in Western blotting, ELISA, IHC, and ICC. It is intended for mouse IgG immunodetection with an HRP-compatible substrate and should not be assumed suitable for non-mouse primaries, fluorescence-only workflows, or unvalidated sorting and purification procedures.

• Bufuralol (hydrochloride): Assay Reliability

  2026-08-11

  A practical, scenario-driven guide to using Bufuralol (hydrochloride) SKU C5043 in viability, proliferation, cytotoxicity, and human-relevant organoid workflows. It connects β-adrenergic pharmacology with solvent control, data interpretation, and evidence-based product selection.

• Cyclophilin A Drives Cyclosporin Immunosuppression

  2026-08-10

  Colgan et al. used Ppia-deficient mice and immune-cell assays to test whether Cyclophilin A is required for Cyclosporin A-mediated immunosuppression. Their results identify CypA as the primary mediator linking cyclosporine binding to impaired calcineurin signaling, inhibition of T-cell activation, and loss of responses to allogeneic challenge.

15645 records 1/1043 page Next 12345 下5页 Last page